Is there any domestic drug for Imatinib and analysis of its price and availability?

Imatinib (Imatinib), as a classic targeted drug for the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST), has long been on the market in China, and there are domestic generic versions. Many domestic pharmaceutical companies, such as Chia Tai Tianqing, Hansoh Pharmaceuticals, CSPC Ouyi, etc., have produced domestic imatinib that meets quality standards, giving patients more affordable and affordable options in addition to imported original drugs. This also greatly improves the accessibility of drugs, allowing more patients to adhere to treatment in the long term.

In terms of price, the domestically produced imatinib drug has significantly reduced its cost. The most common domestic specifications are 100 mg and 60 tablets. The price of a box is about six to seven hundred yuan, and it has been included in the scope of medical insurance reimbursement, so the actual out-of-pocket burden on patients is lighter. In comparison, the price of original drugs was once higher, but with the advancement of centralized procurement policies, the overall gap has gradually narrowed. In the foreign market, Indian generic drugs are cheaper. The price of 100 mg 120 tablets is about three to four hundred yuan, which is even lower than domestically produced drugs. It has become the choice of some patients to obtain it through overseas channels.

From the perspective of efficacy and safety, the clinical effects of domestic generic imatinib and the original drug are similar, and both can effectively inhibit the activity of the BCR-ABL fusion gene and control the development of the disease. Multiple studies have shown that the molecular response rate and hematological response rate of domestically produced drugs in patients with chronic phase CML are not much different from those of the original drugs. This means that if patients have limited economic conditions, choosing domestic drugs or Indian generic drugs will not significantly affect the treatment effect.

Generally speaking, the availability of imatinib in China is very high. Whether it is the original drug or a domestic generic drug, patients can obtain it in regular hospital pharmacies. Combined with the medical insurance reimbursement policy, domestically produced drugs reduce the financial pressure of long-term treatment for patients. If you pursue medication stability and formal channels, domestically produced or imported original drugs are the better choices; and if the financial burden is high, some patients will also consider obtaining Indian generic drugs through formal overseas channels. The final medication plan should be based on the condition, financial conditions and doctor's advice to achieve individualized and reasonable selection.

Reference materials:https://www.drugs.com/